Asian Thoracic Oncology Research Group (ATORG) Expert Consensus Statement on MET Alterations in NSCLC: Diagnostic and Therapeutic Considerations

•MET alterations are associated with tumorigenesis and TKI resistance in patients with non-small cell lung cancer (NSCLC)•ATORG provides recommendations for diagnosis of (Mesenchymal Epithelial Transition) MET alterations in NSCLC•ATORG recommends MET exon 14 testing within panels for driver mutatio...

Full description

Saved in:
Bibliographic Details
Published inClinical lung cancer Vol. 23; no. 8; pp. 670 - 685
Main Authors Ahn, Myung-Ju, Mendoza, Marvin Jonne L., Pavlakis, Nick, Kato, Terufumi, Soo, Ross A., Kim, Dong-Wan, Liam, Chong Kin, Hsia, Te-Chun, Lee, Chee Khoon, Reungwetwattana, Thanyanan, Geater, Sarayut, Chan, Oscar Siu Hong, Prasongsook, Naiyarat, Solomon, Benjamin J., Nguyen, Thi Thai Hoa, Kozuki, Toshiyuki, Yang, James Chih-Hsin, Wu, Yi-Long, Mok, Tony Shu Kam, Tan, Daniel Shao-Weng, Yatabe, Yasushi
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.12.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:•MET alterations are associated with tumorigenesis and TKI resistance in patients with non-small cell lung cancer (NSCLC)•ATORG provides recommendations for diagnosis of (Mesenchymal Epithelial Transition) MET alterations in NSCLC•ATORG recommends MET exon 14 testing within panels for driver mutations in NSCLC•MET inhibitors can be considered for first or subsequent lines of treatment•Enrolment of patients is encouraged in combination trials of tyrosine kinase inhibitors (TKIs) and MET inhibitors Non-small cell lung cancer (NSCLC) is a heterogeneous disease, with many oncogenic driver mutations, including de novo mutations in the Mesenchymal Epithelial Transition (MET) gene (specifically in Exon 14 [ex14]), that lead to tumourigenesis. Acquired alterations in the MET gene, specifically MET amplification is also associated with the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in patients with EGFR-mutant NSCLC. Although MET has become an actionable biomarker with the availability of MET-specific inhibitors in selected countries, there is differential accessibility to diagnostic platforms and targeted therapies across countries in Asia-Pacific (APAC). The Asian Thoracic Oncology Research Group (ATORG), an interdisciplinary group of experts from Australia, Hong Kong, Japan, Korea, Mainland China, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam, discussed testing for MET alterations and considerations for using MET-specific inhibitors at a consensus meeting in January 2022, and in subsequent offline consultation. Consensus recommendations are provided by the ATORG group to address the unmet need for standardised approaches to diagnosing MET alterations in NSCLC and for using these therapies. MET inhibitors may be considered for first-line or second or subsequent lines of treatment for patients with advanced and metastatic NSCLC harbouring MET ex14 skipping mutations; MET ex14 testing is preferred within multi-gene panels for detecting targetable driver mutations in NSCLC. For patients with EGFR-mutant NSCLC and MET amplification leading to EGFR TKI resistance, enrolment in combination trials of EGFR TKIs and MET inhibitors is encouraged.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:1525-7304
1938-0690
DOI:10.1016/j.cllc.2022.07.012